SCLX Stock — Scilex Holding Company: Cash, EV, Pipeline

What they do

The Company We are an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. We target indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes.

Source: 10-K FY2025 via SEC EDGAR

Share price

$1.70

Market cap

$14.4M

Cash

$0.6M

Enterprise value

$94.6M

Balance sheet

Cash	$0.6M
Debt	$80.8M
Net cash	-$80.2M
Enterprise value	$94.6M
Basic shares	8.5M shares
Fully diluted shares	17.1M shares
Fully diluted market cap	$29.0M
Cash per share	$0.07
Quarterly burn	$6.7M
Cash runway	0.1 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

8.5M

Pre-funded warrants

0.0M

Options

1.5M

RSUs

0.0M

Warrants

6.8M

Converts

0.3M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

17.1M

Cap table as of 2026-06-30.

Price history

Loading SCLX daily closes…

Loading price history…

Upcoming catalysts

No upcoming catalysts on file for this company.

Full readout calendar →

Pipeline assets

SP-102

Phase 3 · Active Modality: dexamethasone sodium phosphate viscous gel for epidural injection

Aliases SEMDEXA

Indications

lumbosacral radicular pain (sciatica) (Phase 3)

Status note Second Phase 3 study initiated September 2025; no discontinuation disclosed.

SP-103

Phase 2 · Active Modality: lidocaine topical system

Partnerships RoyaltyVest (ex-U.S. licensee for lidocaine products)

Indications

chronic neck pain (Phase 2)
acute low back pain (Phase 2 completed) (Phase 2)

Status note Phase 2 trial in acute low back pain completed; being developed for chronic neck pain; no discontinuation disclosed.

SP-104

Phase 1 · Active Modality: delayed-release oral capsule (low-dose naltrexone hydrochloride)

Partnerships Aardvark Therapeutics (asset/IP acquisition)

Indications

fibromyalgia (Phase 1)

Status note Phase 1 trials completed; company states it is committed to pursuing clinical development for fibromyalgia; no discontinuation disclosed.

ZTlido

Approved · Active Modality: lidocaine topical system

Partnerships RoyaltyVest (ex-U.S. licensee); Oishi Koseido (product development agreement)

Indications

neuropathic pain associated with postherpetic neuralgia (PHN) (Approved)

Status note FDA-approved prescription lidocaine topical system 1.8%; commercial product.

ELYXYB

Approved · Active Modality: oral solution (celecoxib)

Partnerships BioDelivery Sciences International and Collegium Pharmaceutical (rights acquisition); Dr. Reddy's Laboratories (know-how/patent license obligations assumed)

Indications

acute treatment of migraine with or without aura in adults (Approved)

Status note FDA-approved ready-to-use oral solution; commercial product.

GLOPERBA

Approved · Active Modality: oral solution (colchicine)

Partnerships Romeg (RxOmeg Therapeutics) (license and commercialization agreement)

Indications

prophylaxis of painful gout flares in adults (Approved)

Status note FDA-approved liquid oral colchicine; commercial product.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

None of the tracked specialist funds reported a position in the latest 13F snapshot.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

SCLX — Scilex Holding Company ☆

What they do

Balance sheet

Share structure

Price history

Upcoming catalysts

Pipeline assets

Specialist fund holders

Latest news

SCLX — Scilex Holding Company